12/15/2023 at 12:00 PM EST
The treatment landscape for CLL has changed dramatically in the past 10 years. With three approved BTK inhibitors, and several more on the horizon, choosing which agent to use in the first-line continues to present a challenge to hematologists/oncologists and care teams. As the choice of first-line agent has ramifications for future lines of therapy, hematologists/oncologists need to be able to map out the treatment journey while keeping in mind that therapy resistance or intolerance may arise and that AEs may diminish adherence to therapy.
In this Creative Educational Concepts Live Webcast, expert faculty will guide learners through the latest clinical data that informs best practices (including sequencing BTKis), the rationale and support for combination therapies, and the need to factor in the needs and preferences of patients.
At the conclusion of this activity, learners will be able to better:
Supported through independent educational grants from AstraZeneca Pharmaceuticals and Lilly USA, LLC.
Hematologist oncologists and allied oncology health care practitioners (HCPs) including oncology pharmacists, nurses, nurse practitioners (NPs), and physician associates (PAs)
In support of improving patient care, Creative Educational Concepts, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Creative Educational Concepts, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Creative Educational Concepts, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 12/15/2024. PAs should only claim credit commensurate with the extent of their participation.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points in the following ILNA subject areas: Care of the Pediatric Hematology and Oncology Patient, Cellular Collection, Preparative Regimens and Infusion, Foundations of Transplant, Oncologic Emergencies, Oncology Nursing Practice, Pediatric Hematology and Oncology Nursing Practice, Professional Practice/Performance, Symptom Management, Palliative Care, Supportive Care, Transplant Process and Infusion, and Treatment categories.
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education Credit for learning and change.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
This Application-based activity is approved for 1.50 contact hours ( 0.15 CEUs) of continuing pharmacy credit (JA0007101-0000-23-013-L01-P).
Dr. Rogers reports the following financial relationships:
Advisory Board: AbbVie Inc.; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; LOXO@Lilly; and Pharmacyclics LLC
Consultant: AbbVie Inc. and Pharmacyclics LLC
Research Support: AbbVie Inc.; Genentech, Inc.; and Novartis (paid to institution)
Dr. Faiman reports the following financial relationships:
Consultant: Bristol Myers Squibb Company; Janssen Pharmaceuticals, Inc; Karyopharm; Pfizer Inc.; and Sanofi
The following individuals have no financial relationships to disclose:
Rebecca Vargas-Jackson, MD (Peer Reviewer)
Nichole Lainhart (Planning Committee)
Keshia Pitt, PhD (Planning Committee)
David Modrak, PhD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Call us at 859-260-1717 • email@example.com